MCID: SMT008
MIFTS: 50

Smith-Magenis Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Fetal diseases

Aliases & Classifications for Smith-Magenis Syndrome

About this section
Sources:
49OMIM, 11diseasecard, 21GeneReviews, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 51Orphanet, 67UniProtKB/Swiss-Prot, 65UMLS, 68Wikipedia, 24GTR, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Smith-Magenis Syndrome:

Name: Smith-Magenis Syndrome 49 11 21 45 22 23 47 51 67 65
Sms 45 23 67
Chromosome 17p Deletion Syndrome 23 65
Smith Magenis Syndrome 68 24
17p11.2 Monosomy 23 65
Chromosome 17p11.2 Deletion Syndrome 45
17p11.2 Microdeletion Syndrome 51
Deletion 17p Syndrome 23
 
Partial Monosomy 17p 23
Chromosome Deletion 65
Del(17)(p11.2) 22
17p- Syndrome 23
P11.2 21
Del 21
17 21

Characteristics:

Orphanet epidemiological data:

51
smith-magenis syndrome:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy

HPO:

61
smith-magenis syndrome:
Inheritance: sporadic, autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 182290
Orphanet51 819
ICD10 via Orphanet28 Q93.5
MESH via Orphanet37 D058496
UMLS via Orphanet66 C0795864
UMLS65 C0795864, C0008628, C3683846 C3661485, more

Summaries for Smith-Magenis Syndrome

About this section
NIH Rare Diseases:45 Smith-magenis syndrome is a developmental disorder that affects many parts of the body. the major features of this condition include mild to moderate intellectual disability, delayed speech and language skills, distinctive facial features, sleep disturbances, and behavioral problems. most people with smith-magenis syndrome have a deletion of genetic material from a specific region of chromosome 17. although this region contains multiple genes, researchers believe that the loss of one particular gene, rai1, in each cell is responsible for most of the characteristic features of the condition. smith-magenis syndrome is not typically inherited, but results from a genetic change that occurs during the formation of reproductive cells (eggs or sperm) or in early fetal development. last updated: 8/22/2014

MalaCards based summary: Smith-Magenis Syndrome, also known as sms, is related to spinocerebellar ataxia 17 and trisomy 17 mosaicism, and has symptoms including cognitive impairment, tented upper lip vermilion and reduced number of teeth. An important gene associated with Smith-Magenis Syndrome is RAI1 (Retinoic Acid Induced 1), and among its related pathways are and Urea cycle and metabolism of amino groups. Affiliated tissues include thymus, kidney and myeloid.

Genetics Home Reference:23 Smith-Magenis syndrome is a developmental disorder that affects many parts of the body. The major features of this condition include mild to moderate intellectual disability, delayed speech and language skills, distinctive facial features, sleep disturbances, and behavioral problems.

UniProtKB/Swiss-Prot:67 Smith-Magenis syndrome: Characterized by congenital mental retardation associated with development and growth delays. Affected persons have characteristic behavioral abnormalities, including self-injurious behaviors and sleep disturbance, and distinct craniofacial and skeletal anomalies.

Description from OMIM:49 182290

GeneReviews summary for NBK1310

Related Diseases for Smith-Magenis Syndrome

About this section

Diseases related to Smith-Magenis Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 223)
idRelated DiseaseScoreTop Affiliating Genes
1spinocerebellar ataxia 1712.5
2trisomy 17 mosaicism12.4
3ciliary dyskinesia, primary, 1712.4
4retinitis pigmentosa 1712.4
5amyotrophic lateral sclerosis 1712.4
6mental retardation, autosomal dominant 1712.4
7combined oxidative phosphorylation deficiency 1712.4
8sm-ahnmd12.4
9inflammatory bowel disease 17, protection against12.4
10schizophrenia 1712.4
11joubert syndrome 1712.4
12spinocerebellar ataxia, autosomal recessive 1712.4
13parkinson disease 1712.4
14epileptic encephalopathy, early infantile, 1712.4
15cardiomyopathy, hypertrophic, 1712.4
16bardet-biedl syndrome 1712.4
17leber congenital amaurosis 1712.4
18autism susceptibility 1712.4
19immunodeficiency 17, cd3 gamma deficient12.4
20deafness, autosomal dominant 1712.4
21hypogonadotropic hypogonadism 17 with or without anosmia12.3
22bleeding disorder, platelet-type, 1712.3
23cataract 17, multiple types12.3
24spastic paraplegia 1712.3
25myasthenic syndrome, congenital, 1712.3
26ring chromosome 1712.2
27cone-rod dystrophy 1712.2
28alzheimer disease 1712.2
29mental retardation, x-linked, syndromic 1712.2
30deafness, autosomal dominant nonsyndromic sensorineural 1712.2
31dystonia 1712.2
32deafness, autosomal recessive 1712.2
33diabetes mellitus, insulin-dependent, 1712.2
34mosaic trisomy 1712.1
35snyder-robinson syndrome11.9
36leukemia, acute promyelocytic, somatic11.7
37long qt syndrome-1011.7
3816p11.2 deletion syndrome11.6
39chromosome 17p deletion11.6
40osteogenesis imperfecta, type xvii11.6
4117-alpha-hydroxylase/17,20-lyase deficiency11.6
42chromosome 17q23.1-q23.2 deletion syndrome11.6
43silver spastic paraplegia syndrome11.6
44mental retardation, x-linked, snyder-robinson type11.5
45koolen-de vries syndrome11.5
46dementia, frontotemporal11.4
47potocki-lupski syndrome11.4
48chromosome 17p duplication11.4
49corneal dystrophy, congenital stromal11.4
50extratemporal epilepsy11.4

Graphical network of the top 20 diseases related to Smith-Magenis Syndrome:



Diseases related to smith-magenis syndrome

Symptoms for Smith-Magenis Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

182290

Clinical features from OMIM:

182290

Symptoms:

 51 (show all 72)
  • brachycephaly/flat occiput
  • frontal bossing/prominent forehead
  • broad forehead
  • large face
  • upslanted palpebral fissures/mongoloid slanting palpebral fissures
  • deepset eyes/enophthalmos
  • mid-facial hypoplasia/short/small midface
  • synophris/synophrys
  • broad nose/nasal bridge
  • depressed nasal bridge
  • tented upper lip
  • taurodontia
  • anodontia/oligodontia/hypodontia
  • short hand/brachydactyly
  • respiratory-digestive intersection/aero-digestive cross-roads anomaly
  • abnormal cry/voice/phonation disorder/nasal speech
  • tics/stereotypias
  • hypotonia
  • areflexia/hyporeflexia
  • sleep and vigilance disorders
  • speech troubles/aphasia/dysphasia/echolalia/mutism/logorrhea/dysprosodia
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • hyperactivity/attention deficit
  • humour troubles/anxiety/depression/apathy/euphoria/irritability
  • auto-aggressivity/auto-mutilation
  • insterstitial/subtelomeric microdeletion/deletion
  • generalized obesity
  • hypertelorism
  • prognathism/prognathia
  • micrognathia/retrognathia/micrognathism/retrognathism
  • microcornea
  • myopia
  • strabismus/squint
  • short/small nose
  • anteverted nares/nostrils
  • mouth held open
  • short philtrum
  • macroglossia/tongue protrusion/proeminent/hypertrophic
  • hyperacusia
  • conductive deafness/hearing loss
  • chronic/relapsing otitis
  • scoliosis
  • abnormal vertebral size/shape
  • clinodactyly of fifth finger
  • flat foot
  • syndactyly of toes
  • gastroesophageal reflux/pyrosis/esophagitis/hiatal hernia/gastroparesia
  • constipation
  • congenital cardiac anomaly/malformation/cardiopathy
  • dilated cerebral ventricles without hydrocephaly
  • corpus callosum/septum pellucidum total/partial agenesis
  • peripheral neuropathy
  • eeg anomalies
  • abnormal gait
  • insensitivity to pain
  • hyperlipidemia/hypercholesterolemia/hypertriglyceridemia
  • short stature/dwarfism/nanism
  • failure to thrive/difficulties for feeding in infancy/growth delay
  • fetal immobility/abnormal fetal movements
  • microcephaly
  • retinal detachment
  • cleft lip
  • cleft palate without cleft lip/submucosal cleft palate/bifid uvula
  • upper limb polydactyly/hexadactyly
  • agenesis/hypoplasia/aplasia of kidneys
  • ectopic/horseshoe/fused kidneys
  • ureter/calyx/pelvis duplication/bifid/retrocava/retroiliac ureter
  • hypothyroidy
  • precocious puberty
  • late puberty/hypogonadism/hypogenitalism
  • seizures/epilepsy/absences/spasms/status epilepticus
  • restricted joint mobility/joint stiffness/ankylosis

HPO human phenotypes related to Smith-Magenis Syndrome:

(show all 99)
id Description Frequency HPO Source Accession
1 cognitive impairment hallmark (90%) HP:0100543
2 tented upper lip vermilion hallmark (90%) HP:0010804
3 reduced number of teeth hallmark (90%) HP:0009804
4 attention deficit hyperactivity disorder hallmark (90%) HP:0007018
5 depressed nasal bridge hallmark (90%) HP:0005280
6 sleep disturbance hallmark (90%) HP:0002360
7 neurological speech impairment hallmark (90%) HP:0002167
8 frontal bossing hallmark (90%) HP:0002007
9 obesity hallmark (90%) HP:0001513
10 brachydactyly syndrome hallmark (90%) HP:0001156
11 stereotypic behavior hallmark (90%) HP:0000733
12 taurodontia hallmark (90%) HP:0000679
13 synophrys hallmark (90%) HP:0000664
14 upslanted palpebral fissure hallmark (90%) HP:0000582
15 deeply set eye hallmark (90%) HP:0000490
16 broad forehead hallmark (90%) HP:0000337
17 malar flattening hallmark (90%) HP:0000272
18 everted upper lip vermilion common (75%) HP:0010803
19 morphological abnormality of the middle ear common (75%) HP:0008609
20 short palm common (75%) HP:0004279
21 sleep disturbance common (75%) HP:0002360
22 hoarse voice common (75%) HP:0001609
23 abnormality of the larynx common (75%) HP:0001600
24 generalized hypotonia common (75%) HP:0001290
25 hyporeflexia common (75%) HP:0001265
26 global developmental delay common (75%) HP:0001263
27 broad palm common (75%) HP:0001169
28 brachydactyly syndrome common (75%) HP:0001156
29 delayed speech and language development common (75%) HP:0000750
30 self-mutilation common (75%) HP:0000742
31 stereotypic behavior common (75%) HP:0000733
32 deeply set eye common (75%) HP:0000490
33 mandibular prognathia common (75%) HP:0000303
34 broad face common (75%) HP:0000283
35 malar flattening common (75%) HP:0000272
36 brachycephaly common (75%) HP:0000248
37 hyperacusis typical (50%) HP:0010780
38 aplasia/hypoplasia of the corpus callosum typical (50%) HP:0007370
39 impaired pain sensation typical (50%) HP:0007328
40 abnormality of the tracheobronchial system typical (50%) HP:0005607
41 short stature typical (50%) HP:0004322
42 clinodactyly of the 5th finger typical (50%) HP:0004209
43 abnormal form of the vertebral bodies typical (50%) HP:0003312
44 short nose typical (50%) HP:0003196
45 hypercholesterolemia typical (50%) HP:0003124
46 scoliosis typical (50%) HP:0002650
47 eeg abnormality typical (50%) HP:0002353
48 hypertriglyceridemia typical (50%) HP:0002155
49 ventriculomegaly typical (50%) HP:0002119
50 constipation typical (50%) HP:0002019
51 toe syndactyly typical (50%) HP:0001770
52 pes planus typical (50%) HP:0001763
53 prenatal movement abnormality typical (50%) HP:0001557
54 gait disturbance typical (50%) HP:0001288
55 synophrys typical (50%) HP:0000664
56 myopia typical (50%) HP:0000545
57 strabismus typical (50%) HP:0000486
58 microcornea typical (50%) HP:0000482
59 anteverted nares typical (50%) HP:0000463
60 wide nasal bridge typical (50%) HP:0000431
61 conductive hearing impairment typical (50%) HP:0000405
62 otitis media typical (50%) HP:0000388
63 abnormality of the outer ear typical (50%) HP:0000356
64 micrognathia typical (50%) HP:0000347
65 short philtrum typical (50%) HP:0000322
66 hypertelorism typical (50%) HP:0000316
67 mandibular prognathia typical (50%) HP:0000303
68 velopharyngeal insufficiency typical (50%) HP:0000220
69 open mouth typical (50%) HP:0000194
70 abnormality of the tongue typical (50%) HP:0000157
71 abnormality of cardiovascular system morphology frequent (33%) HP:0030680
72 seizures frequent (33%) HP:0001250
73 abnormal localization of kidney occasional (7.5%) HP:0100542
74 renal hypoplasia/aplasia occasional (7.5%) HP:0008678
75 abnormality of the forearm occasional (7.5%) HP:0002973
76 limitation of joint mobility occasional (7.5%) HP:0001376
77 seizures occasional (7.5%) HP:0001250
78 hand polydactyly occasional (7.5%) HP:0001161
79 precocious puberty occasional (7.5%) HP:0000826
80 hypothyroidism occasional (7.5%) HP:0000821
81 retinal detachment occasional (7.5%) HP:0000541
82 microcephaly occasional (7.5%) HP:0000252
83 cleft upper lip occasional (7.5%) HP:0000204
84 cleft palate occasional (7.5%) HP:0000175
85 abnormality of the genital system occasional (7.5%) HP:0000078
86 abnormality of the ureter occasional (7.5%) HP:0000069
87 abnormal renal morphology HP:0012210
88 head-banging HP:0012168
89 midface retrusion HP:0011800
90 areflexia HP:0001284
91 intellectual disability HP:0001249
92 short stature HP:0004322
93 sleep disturbance HP:0002360
94 hoarse voice HP:0001609
95 muscular hypotonia HP:0001252
96 brachydactyly syndrome HP:0001156
97 hyperactivity HP:0000752
98 self-mutilation HP:0000742
99 stereotypic behavior HP:0000733

Drugs & Therapeutics for Smith-Magenis Syndrome

About this section

Drugs for Smith-Magenis Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 127)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Methylphenidateapproved, investigationalPhase 4364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
2
DopamineapprovedPhase 4308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3
Risperidoneapproved, investigationalPhase 4477106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
 
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperdal M-tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone M-tab
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4Peripheral Nervous System AgentsPhase 4, Phase 1, Phase 218510
5Adrenergic AgentsPhase 44204
6Neurotransmitter AgentsPhase 414795
7Vasodilator AgentsPhase 4, Phase 22926
8CeliprololPhase 42
9Adrenergic AntagonistsPhase 41253
10Adrenergic beta-1 Receptor AntagonistsPhase 4292
11Adrenergic beta-AntagonistsPhase 4979
12Antihypertensive AgentsPhase 4, Phase 23618
13Anti-Arrhythmia AgentsPhase 42371
14Neurotransmitter Uptake InhibitorsPhase 42857
15Dopamine Uptake InhibitorsPhase 4925
16Dopamine AgentsPhase 43084
17Central Nervous System StimulantsPhase 41721
18
LenalidomideapprovedPhase 3, Phase 2, Phase 1674191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide
19
MelphalanapprovedPhase 3, Phase 2685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
20
ClonidineapprovedPhase 31894205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine Hydrochloride
Clonidine Transdermal System
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Kapvay
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Nexiclon
Nexiclon Xr
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
21
IdelalisibapprovedPhase 340870281-82-6
Synonyms:
 
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one
5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one
22
Melatoninapproved, nutraceuticalPhase 3, Phase 123473-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
23
Vitamin Eapproved, nutraceuticalPhase 2, Phase 337159-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-alpha-tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-ol
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'r)-alpha-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-alpha-tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitamin e
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
d-alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
24Central Nervous System DepressantsPhase 3, Phase 110016
25MitogensPhase 3, Phase 21386
26AntioxidantsPhase 3, Phase 12442
27Protective AgentsPhase 3, Phase 1, Phase 25651
28HormonesPhase 3, Phase 1, Phase 211748
29Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
30Anti-Bacterial AgentsPhase 3, Phase 2, Phase 19140
31Angiogenesis InhibitorsPhase 3, Phase 2, Phase 13688
32Immunologic FactorsPhase 3, Phase 2, Phase 118483
33Angiogenesis Modulating AgentsPhase 3, Phase 2, Phase 13611
34Immunosuppressive AgentsPhase 3, Phase 2, Phase 110422
35Interferon-alphaPhase 31028
36interferonsPhase 31930
37VitaminsPhase 2, Phase 33857
38Calcium, DietaryPhase 3, Phase 2, Phase 14678
39AntibodiesPhase 34477
40ImmunoglobulinsPhase 34477
41Antibodies, MonoclonalPhase 32413
42TocopherolsPhase 2, Phase 3376
43TocotrienolsPhase 2, Phase 3372
44arginineNutraceuticalPhase 3364
45TocotrienolNutraceuticalPhase 2, Phase 3372
46Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 3912
47TocopherolNutraceuticalPhase 2, Phase 3376
48
Sirolimusapproved, investigationalPhase 2179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
49
Temozolomideapproved, investigationalPhase 266285622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
50
EverolimusapprovedPhase 21797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus

Interventional clinical trials:

(show top 50)    (show all 89)
idNameStatusNCT IDPhase
1Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypeCompletedNCT00190411Phase 4
2The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeRecruitingNCT00768820Phase 4
3Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] AbnormalityCompletedNCT00179621Phase 3
4Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 YearsRecruitingNCT00546988Phase 3
5Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSRecruitingNCT02231008Phase 2, Phase 3
6Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesRecruitingNCT01906866Phase 3
7Growth Hormone and Chromosome 18q- and Abnormal GrowthActive, not recruitingNCT00134420Phase 3
8A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5qActive, not recruitingNCT01029262Phase 3
9Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaActive, not recruitingNCT01659021Phase 3
10Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the ProstateActive, not recruitingNCT01444820Phase 3
11Effects of PTH Replacement on Bone in HypoparathyroidismActive, not recruitingNCT00395538Phase 3
12Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.Not yet recruitingNCT02070211Phase 2, Phase 3
13OraTest in Combination With Visual Examination and Visual Examination AloneTerminatedNCT00537199Phase 3
14Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent AnaemiaCompletedNCT01338337Phase 2
15Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2
16Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic AbnormalityCompletedNCT00065156Phase 2
17Efficacy of Minoxidil in Children With Williams-Beuren SyndromeCompletedNCT00876200Phase 2
18Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed OligoastrocytomaCompletedNCT00362570Phase 2
19Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor SyndromesCompletedNCT00971789Phase 2
20Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid SyndromeRecruitingNCT02710084Phase 2
21Everolimus With and Without Temozolomide in Adult Low Grade GliomaRecruitingNCT02023905Phase 2
22Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibRecruitingNCT01907607Phase 2
23Immune Disorder HSCT ProtocolRecruitingNCT01821781Phase 2
24Thymus Transplantation Safety-EfficacyRecruitingNCT01220531Phase 1, Phase 2
25Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)Active, not recruitingNCT01525901Phase 2
26RA-2 13-cis Retinoic Acid (Isotretinoin)Active, not recruitingNCT02061384Phase 2
27A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qActive, not recruitingNCT00885508Phase 2
28Phase I/II Thymus Transplantation With Immunosuppression #950Active, not recruitingNCT00579527Phase 1, Phase 2
29Thymus Transplantation Dose in DiGeorge #932Active, not recruitingNCT00576836Phase 2
30Thymus Transplantation in DiGeorge Syndrome #668Active, not recruitingNCT00576407Phase 2
31Sulfamethoxazole for the Treatment of Primary PREPL DeficiencyEnrolling by invitationNCT02640443Phase 2
32A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) PatientsTerminatedNCT00699842Phase 1, Phase 2
33Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial SyndromeTerminatedNCT01127503Phase 2
34Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
35Treatment Strategies for Children With Smith-Magenis SyndromeRecruitingNCT00506259Phase 1
36Thymus Transplantation With ImmunosuppressionActive, not recruitingNCT00579709Phase 1
37Parathyroid and Thymus Transplantation in DiGeorge #931Active, not recruitingNCT00566488Phase 1
38Serum-Free Thymus Transplantation in DiGeorge AnomalyTerminatedNCT00849888Phase 1
39Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards TreatmentCompletedNCT02000167
40Positional Cloning of the Gene(s) Responsible for Alagille SyndromeCompletedNCT00001642
41Study of the Pathophysiological Mechanisms Involved in Bleeding EventsCompletedNCT01314560
42Characterization of WAGR Syndrome and Other Chromosome 11 Gene DeletionsCompletedNCT00758108
43Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion SyndromesCompletedNCT00004351
44Cognitive Remediation in 22q11DSCompletedNCT01781923
45S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood DiseaseCompletedNCT00898066
46Microarray Analysis in Syndromic ObesityCompletedNCT01043198
47Evaluation of Patients With Unresolved Chromosome AbnormalitiesCompletedNCT00001639
48Resolution of Primary Immune Defect in 22q11.2 Deletion SyndromeCompletedNCT02460328
49Role of Pseudogene in Incontinentia Pigmenti, and Its Potential TreatmentCompletedNCT00976586
50SMN Copy Number Distribution in Mali, West AfricaCompletedNCT01059240

Search NIH Clinical Center for Smith-Magenis Syndrome

Genetic Tests for Smith-Magenis Syndrome

About this section

Genetic tests related to Smith-Magenis Syndrome:

id Genetic test Affiliating Genes
1 Smith-Magenis Syndrome22 RAI1

Anatomical Context for Smith-Magenis Syndrome

About this section

MalaCards organs/tissues related to Smith-Magenis Syndrome:

33
Thymus, Kidney, Myeloid, Tongue, Eye, Prostate, Brain

Animal Models for Smith-Magenis Syndrome or affiliated genes

About this section

Publications for Smith-Magenis Syndrome

About this section

Articles related to Smith-Magenis Syndrome:

(show top 50)    (show all 169)
idTitleAuthorsYear
1
Sebaceous hyperplasia of the vulva: a series of cases reporting no association with the Muir-Torre syndrome. (24901406)
2014
2
Optimal management of hereditary hemorrhagic telangiectasia. (25342923)
2014
3
The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. (23372721)
2013
4
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. (24346133)
2013
5
The effect of ghrelin on MK-801 induced memory impairment in rats. (23538209)
2013
6
Hypoxia upregulates the expression of annexin A1 in lung adenocarcinoma a549 cells]. (22613333)
2012
7
Novel report of an adrenal adenoma in a newborn. (22813810)
2012
8
Pregnancies, abortions, and births among women with and without borderline personality disorder. (22749198)
2012
9
Phosphatidylinositol 3-kinase signaling delays sendai virus-induced apoptosis by preventing XIAP degradation. (21367892)
2011
10
Incidence and presentation of fungal sinusitis in patient diagnosed with chronic rhinosinusitis. (22319697)
2010
11
Altered EEG spectral activity and attentional behavioral deficits following prolonged febrile seizures: a pilot study. (19286493)
2009
12
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. (19759354)
2009
13
Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. (19145109)
2009
14
Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. (19448674)
2009
15
Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. (19812054)
2009
16
Alcoholism and alcohol abstinence: N-acetylcysteine to improve energy expenditure, myocardial oxidative stress, and energy metabolism in alcoholic heart disease. (20004343)
2009
17
A case of hypereosinophilic syndrome presenting with intractable gastric ulcers. (20027690)
2009
18
Cervical spondylosis in Nepalese porters. (19079399)
2008
19
Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. (18493841)
2008
20
Implementing the LIM code: the structural basis for cell type-specific assembly of LIM-homeodomain complexes. (18583962)
2008
21
Expression of ephrinB1 and its receptor in glaucomatous optic neuropathy. (17301119)
2007
22
A review of genome mutation and Alzheimer's disease. (17158517)
2007
23
Structure of human TSG101 UEV domain. (16552148)
2006
24
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. (16522681)
2006
25
Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. (17038680)
2006
26
Regulation of cell-cell adhesion by Rap1. (16757338)
2006
27
Nonviral gene transfer of hepatocyte growth factor attenuates neurologic injury after spinal cord ischemia in rabbits. (17000308)
2006
28
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. (15802632)
2005
29
Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. (16115131)
2005
30
Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. (16251238)
2005
31
Thr176 regulates the activity of the mouse nuclear receptor CAR and is conserved in the NR1I subfamily members PXR and VDR. (15610065)
2005
32
Bovine mater-like NALP9 is an oocyte marker gene. (15892040)
2005
33
Nck-2 interacts with focal adhesion kinase and modulates cell motility. (11950595)
2002
34
Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. (11309000)
2001
35
Learning deficits in mice with persistent Borna disease virus infection of the CNS associated with elevated chemokine expression. (11182167)
2001
36
Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. (10949149)
2000
37
A role for protein kinase cepsilon in the inhibitory effect of epidermal growth factor on calcium-stimulated chloride secretion in human colonic epithelial cells. (10801833)
2000
38
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. (10875917)
2000
39
World population data for the HLA-DQA1, PM and D1S80 loci with least and most common profile frequencies for combinations of loci estimated following NRC II guidelines. (10641927)
2000
40
Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. (10092998)
1999
41
Severe progressive deformities after limb lengthening in type-II fibular hemimelia. (10068029)
1999
42
T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine. (10225005)
1999
43
Prenatal ultrasonographic findings of intra-abdominal cystic lymphangioma: a case report. (9142629)
1997
44
Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs. (9263392)
1997
45
Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. (9166797)
1997
46
Effect of concentration of trisodium citrate anticoagulant on calculation of the International Normalised Ratio and the International Sensitivity Index of thromboplastin. (7974381)
1994
47
Histochemical studies on rectal mucosa in active intestinal schistosomiasis. (1908499)
1991
48
Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. (2500843)
1989
49
Autoantibodies, histocompatibility antigens and testosterone in males with alcoholic liver cirrhosis. (6973433)
1981
50
Erythema multiforme in dermatophytosis. (6775223)
1980

Variations for Smith-Magenis Syndrome

About this section

Clinvar genetic disease variations for Smith-Magenis Syndrome:

5 (show all 12)
id Gene Variation Type Significance SNP ID Assembly Location
1RAI1NM_030665.3(RAI1): c.2273G> A (p.Trp758Ter)single nucleotide variantPathogenicrs527236033GRCh37Chr 17, 17698535: 17698535
2RAI1NM_030665.3(RAI1): c.3583A> T (p.Lys1195Ter)single nucleotide variantPathogenicrs727504118GRCh37Chr 17, 17699845: 17699845
3RAI1NM_030665.3(RAI1): c.4678C> T (p.Arg1560Ter)single nucleotide variantPathogenicrs727504119GRCh38Chr 17, 17797626: 17797626
4chr17deletionPathogenic
5RAI1NM_030665.3(RAI1): c.3281C> A (p.Ser1094Ter)single nucleotide variantPathogenicrs376044849GRCh37Chr 17, 17699543: 17699543
6RAI1RAI1, 1-BP DEL, 4929CdeletionPathogenic
7RAI1RAI1, 1-BP DEL, 1308CdeletionPathogenic
8RAI1RAI1, 29-BP DELdeletionPathogenic
9RAI1NM_030665.3(RAI1): c.5423G> A (p.Ser1808Asn)single nucleotide variantPathogenicrs104894633GRCh37Chr 17, 17701685: 17701685
10RAI1NM_030665.3(RAI1): c.4685A> G (p.Gln1562Arg)single nucleotide variantPathogenicrs104894634GRCh37Chr 17, 17700947: 17700947
11RAI1RAI1, 1-BP DEL, 3801CdeletionPathogenic
12RAI1RAI1, 19-BP DELdeletionPathogenic

Expression for genes affiliated with Smith-Magenis Syndrome

About this section
Search GEO for disease gene expression data for Smith-Magenis Syndrome.

Pathways for genes affiliated with Smith-Magenis Syndrome

About this section

Pathways related to Smith-Magenis Syndrome according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.0
2
Show member pathways
10.0RAI1, SMS

GO Terms for genes affiliated with Smith-Magenis Syndrome

About this section

Sources for Smith-Magenis Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet